Held by 4 specialist biotech funds
High Convergence**Signal Note: OrbiMed Initiates $157M EW Position** OrbiMed's new 1.84M share stake in Edwards Lifesciences likely reflects conviction in the company's structural cardiac and interventional cardiology portfolio, particularly as SAPIEN valve franchise adoption accelerates in TAVR and mitral/tricuspid spaces.
AI analyst context — unlock full analysis
**Signal Note: Rock Springs Capital Initiates $7.0M EW Position** Rock Springs' entry into Edwards Lifesciences suggests conviction in near-term catalysts, likely tied to upcoming PASCAL II transcatheter mitral valve replacement data (expected late 2024/early 2025) or sustained structural heart procedure volume recovery post-pandemic. The $7.0M position size is material for a concentrated healthcare specialist, indicating this is a meaningful conviction thesis rather than a tactical trade.
+ 2 more positions with dollar amounts and AI context
Unlock All — 7-Day Free Trial